Dr. Logan Discusses Treatment Options in CLL

Aaron Logan, MD, PhD
Published: Tuesday, Dec 19, 2017



Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).

CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.

Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.
 


Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).

CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.

Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x